2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
09:30 a.m. - 11:00 a.m.
MCCNO - 208-210
Technology and Procedures, Molecular Testing, Treatment Considerations, Artificial Intelligence (AI), Natural Language Processing, Biological Processes, Genomics, Diseases, Bleeding and Clotting, Thromboembolism, Thrombotic Disorders, Lymphoid Malignancies, Plasma Cell Disorders, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult, Elderly, Young Adult
PAPER

33 A matched population-based cohort study to evaluate the risk of major adverse limb events after cancer diagnosis

Willem Brandt, MSc, David Kirkwood, MS2, Mario D'Oria, MD3, Ning Liu, PhD4, Marc Carrier Jr, MD5, Rinku Sutradhar, PhD6, Deborah Michelle Siegal, MD MSc FRCPC7
1 University of Ottawa, Ottawa, Ontario, Canada
2 Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada
3 University of Trieste, Trieste, Italy
4 Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada
5 Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
6 Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada, University of Toronto, Toronto, Ontario, Canada
7 Ottawa Hospital Research Institute, Ottawa, Ontario, Canada

Background

Cancer is increasingly recognized as a risk factor for arterial thrombotic events. However, the risk of major adverse limb events (MALE) including acute limb ischemia, major amputation, and limb revascularization in patients with cancer remains poorly defined. We evaluated the risk of MALE among patients with newly diagnosed cancer versus matched cancer-free controls, using two separate matched cohorts stratified by the absence or presence of pre-existing peripheral artery disease (PAD).

Methods

We conducted a population-based matched cohort study using linked administrative and clinical health databases from Ontario, Canada. Adults aged 66-105 years with a new cancer diagnosis between April 2010 and March 2024 were exact-matched 1:1 by age and sex to cancer-free controls. Separate matched cohorts were created according to the presence or absence of pre-existing PAD. Cancer diagnosis was identified using ICD-O-3 diagnostic codes. The index date was the date of cancer diagnosis for patients with cancer, and a corresponding dummy index date was assigned to the controls. The primary outcome was MALE, defined using ICD-10 codes for PAD as most responsible diagnosis for hospitalization or emergency department visits (to capture acute events), and procedural codes for major amputation or lower-extremity revascularization. The secondary outcomes were all-cause mortality and individual components of MALE. We estimated the cumulative incidence of MALE at 6 months, 12 months, and 5 years, accounting for death as a competing risk.

Results

Cohort 1 (no pre-existing PAD) included 546,102 patients with cancer and 546,102 matched controls (mean age 76 years; 47.2% female). Baseline characteristics were generally similar, though several comorbidity and care-utilization variables differed between groups.  MALE rates were higher among patients with cancer (0.37 per 100 patient-years; 95%CI 0.36-0.38) compared to those without cancer (0.21, 95%CI 0.21-0.22). The cumulative incidence of MALE (with 95%CI) was higher in patients with cancer at 6 months (0.26% [0.25-0.28] vs. 0.10% [0.09-0.11]), 12 months (0.41% [0.39-0.43] vs. 0.20% [0.19-0.21]) and 5 years (1.1% [1.1-1.2] vs. 0.98% [0.95-1.0]). All-cause mortality was also higher in patients with cancer at 6 months (21.0% vs 1.6%), 12 months (28.2% vs 3.2%), and 5 years (51.3% vs 17.1%).".

Cohort 2 (pre-existing PAD) included 9,996 patients with cancer and 9,996 matched controls (mean age 77 years; 35.2% female). Baseline characteristics were generally similar, though several comorbidity and care-utilization variables differed between groups. MALE rates were not statistically different between patients with cancer (6.21 per 100 patient-years; 95%CI 5.84-6.59) and those without cancer (5.87 per 100 patient-years; 95%CI 5.60-6.16). However, the cumulative incidence of MALE (with 95%CI) was lower in patients with cancer at 6 months (3.88% [3.51-4.27] vs. 5.26% [4.83-5.72], 12 months (5.82% [5.37-6.29] vs. 7.82% [7.30-8.35]), and 5 years (11.1% [10.4-11.7] vs. 18.3% [17.5-19.1]). The cumulative incidence of all-cause mortality was higher in patients with cancer compared to cancer free controls at 6 months (34.8% vs. 6.55%), 12 months (44.7% vs. 11.9%), and 5 years (71.0% vs. 40.9%).

Conclusions

Compared with matched cancer-free controls, patients with newly diagnosed cancer and no prior PAD had a higher rate and cumulative incidence of MALE for up to 5 years, with the greatest relative increase (3-fold) occurring within the first 6 months after diagnosis. Among patients with pre-existing PAD, MALE event rates were not statistically different, however, the cumulative incidence was lower likely due to the greater competing risk of death. These findings highlight the importance of considering both arterial thrombotic risk and competing mortality when evaluating patients with newly diagnosed cancer, particularly those with pre-existing PAD. Although mortality was higher in patients with cancer than cancer-free controls in both cohorts, patients with cancer and a history of PAD experienced the highest risk of death, suggesting that PAD is a prognostically important comorbidity to consider at cancer diagnosis.

Willem Brandt, MSc: No relevant conflicts of interest to declare.